QurAlis
Cambridge, Massachusetts, United States · Biotechnology, Healthcare, Health Care
QurAlis is a pioneering neuroscience company dedicated to developing precision medicines that target the root causes of neurodegenerative and neurological diseases. With leading expertise in amyotrophic lateral sclerosis (ALS), the company is committed to translating scientific breakthroughs into transformative therapies. Guided by collaboration, scientific rigor, and compassion, QurAlis is advanc
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 94
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Private
- Website
- quralis.com
- Company page
Recent activity at QurAlis
QurAlis funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Venture | $20.0M |
| Mar 2023 | Venture | $60.0M |
| Mar 2023 | Series B | $88.0M |
| Sep 2022 | Venture | $5.0M |
| May 2020 | Venture | $33.2M |
Leadership
- Sandy (Klein) Hinckley, Head of Discovery, Senior Director
- Anne Whitaker, Director
- Michael Hutton, Director
- Jonathan Behr, Director
- Johannes Fruehauf, Director
- Luc Dochez, Director
- Roel Bulthuis, Director
- Amy Schulman, Director
- Kasper Roet, Director, Executive Officer, Promoter
- Kasper Roet, Director, Executive Officer, Promoter
- Amy Schulman, Director
- Roel Bulthuis, Director
Verified email and direct lines for QurAlis’s decision-makers are on Fundz. See plans
Employee benefit plans
QurAlis files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
QurAlis in the news
- QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS - BioSpace (May 05, 2026)
- QurAlis announces Phase I QRL-101 trial topline results in ALS - Clinical Trials Arena (Dec 30, 2025)
- QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases - PR Newswire (Mar 09, 2023)
- Eli Lilly adds ALS drug prospect with QurAlis deal - BioPharma Dive (Jun 03, 2024)
- QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS - BioSpace (Feb 23, 2026)
- Neuroscience-focused biotech doubles space with new Alewife HQ - The Business Journals (Jun 18, 2025)
- QurAlis and Unlearn Announce Collaboration to Accelerate and Optimize ALS Clinical Trials With Generative Artificial Intelligence Technologies - PR Newswire (Jun 27, 2023)
- New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022 - frontiersin.org (Feb 07, 2024)
Companies similar to QurAlis
- Passage Bio · Biotechnology, Healthcare, Health Care, Therapeutics
- Verastem Oncology · Biotechnology, Healthcare, Health Care, Therapeutics
- Verrica · Biotechnology, Healthcare, Health Care, Therapeutics
- Biofrontera · Biotechnology, Healthcare, Health Care, Therapeutics
- ClearPoint Neuro · Biotechnology, Healthcare, Health Care, Therapeutics
About QurAlis: questions and answers
What does QurAlis do?
QurAlis is a pioneering neuroscience company dedicated to developing precision medicines that target the root causes of neurodegenerative and neurological diseases. With leading expertise in amyotrophic lateral sclerosis (ALS), the company is committed to translating scientific breakthroughs into transformative therapies. Guided by collaboration, scientific rigor, and compassion, QurAlis is advanc
Where is QurAlis headquartered?
QurAlis is headquartered in Cambridge, Massachusetts, United States.
How many employees does QurAlis have?
QurAlis has about 94 employees.
Has QurAlis raised funding?
Yes. Fundz has recorded 5 funding events for QurAlis. The most recent, $20.0M, was in Sep 2025.
What is the latest news on QurAlis?
On Nov 10, 2025, QurAlis Appoints Manoj Malhotra, M.D., as Chief Medical Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy